Evidence map›Paper›PMID 40476286›Full record

ArticleJournal of radiosurgery and SBRT2025

Stereotactic ablative radiation therapy for pulmonary metastases from sarcoma primaries: A systematic review and meta-analysis of safety and efficacy.

Raj Singh, Robert Sierra, Casey Leimbach, Sidharth Iyer, Eric J Lehrer, Haley Perlow, Rituraj Upadhyay, Sung Jun Ma, Austin Sim, Emile Gogineni and 6 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of radiosurgery and SBRT, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Raj SinghDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Robert SierraDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Casey LeimbachDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Sidharth IyerDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Eric J LehrerDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Haley PerlowDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Rituraj UpadhyayDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Sung Jun MaDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Austin SimDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Emile GogineniDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Sujith BaligaDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Daniel M TrifilettiDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Joshua D PalmerDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
David J KonieczkowskiDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Jeremy BrownsteinDepartment of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Nicholas G ZaorskyDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Funding

NCI NIH HHS L30 CA231572
6 · The paper itself

Abstract

Background: Though promising retrospective and prospective studies have reported on stereotactic ablative radiation therapy(SABR) for management of lung metastases from sarcoma primaries, they are limited by small patient numbers. Methods: The primary outcomes of interest were 1-year and 2-year local control (LC) and Grade 3-5 toxicities. Secondary outcomes were 1-year overall survival (OS) and 2-year OS. Weighted random effects meta-analyses using the DerSimonian and Laird methods were performed to calculate effect sizes. Results: Thirteen studies were identified with 533 patients and 940 lung metastases. The median prescription dose was 50 Gy (range: 48-60 Gy) in 5 fractions (range: 4-10). Following SABR, 1- and 2-year pooled LC rates were 97% (95% CI: 95-98%) and 91% (95% CI: 88-95%), respectively. Pooled 1- and 2-year OS rates were 85% (95% CI: 80-90%) and 68% (95% CI: 57-80%), respectively. The estimated incidence of Grade 3-5 toxicities following SABR was 0.1% (95% CI: 0-0.5%). Conclusion: SABR for sarcoma pulmonary metastases resulted in excellent LC with minimal toxicities.

Indexed as

local controllung metastasesoverall survivalsarcoma metastasesstereotactic ablative radiation therapytoxicity

Identifiers

PMID40476286
PMCPMC12136686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.